The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations–The Lung Cancer Mutation Consortium (LCMC2) - Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., Haura, E., Politi, K., Glisson, B., Cetnar, J., Garon, E. B., Schiller, J., Waqar, S. N., Sequist, L. V., Brahmer, J., Shyr, Y., Kugler, K., Wistuba, I. I., Johnson, B. E., Minna, J. D., Kris, M. G., Bunn, P. A., Kwiatkowski, D. J., for the LCMC2 investigators (The American Association for Cancer Research (AACR), 2018)
6182350